Heather Cohen, Ph.D., et al. Preclinical Evaluation of JTX-8064, an Anti-LILRB2 Antagonist Antibody, for Reprogramming Tumor-Associated Macrophages. Presented at AACR Annual Meeting, April 3, 2019.
Contact Us
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Eric Laub
(857) 259-3853 elaub@jouncetx.com